Arteriovenous malformations (AVMs) are congenital vascular anomalies comprised of an abnormal number of blood vessels that are abnormally constructed. The blood vessels directly shunt blood from arterial input to the venous system without an intervening capillary network to dampen pressure. Both abnormal blood vessel construction and abnormal blood flow lead to a risk of rupture and intracranial hemorrhage. In addition, patients with lobar vascular malformations may suffer from intractable vascular headaches or develop seizure disorders. The annual incidence of AVM recognition is thought to be ϳ10,000 patients per year in the United States. However, the reliance on magnetic resonance imaging (MRI) has led to an increasing recognition of these vascular anomalies even in patients with minimal symptoms. The decision making relative to management of an AVM must be carefully evaluated based on several risk factors. The options for management include observation, endovascular embolization alone or in preparation for other adjuvant management, craniotomy and surgical removal, and stereotactic radiosurgery (SRS). 1 All treatments may be done in one or more stages.
In general, the following factors are evaluated when a patient is seen with an AVM: the patient's age, associated medical condition, history of a prior hemorrhagic event, prior management if any, overall volume and morphology, location of the AVM, initial presenting symptoms (headache, seizures, and local neurologic deficits), the AVM angioarchitecture (e.g., compact vs diffuse nidus), estimation of its surgical risks, presence of a proximal or intranidal aneurysm, and prior surgical experience in training. In making a decision for management strategies, we often employ a decision tree algorithm as shown in Fig. 5.1 .
Optimal care depends on careful weighing of each of the above factors and the estimated risk of subsequent hemorrhage. The patient's clinical presentation and location are important issues as well as symptoms in each patient. Age, prior bleeding event, smaller AVM size, deep venous drainage, and high flow rates have been suggested by some as increasing the potential for subsequent bleeding. For larger volume AVM (average diameter 4-5 cm), observation may be the only reasonable strategy in view of the risks of even multimodality management. 2 This may be especially true for patients who have never bled previously. Endovascular embolization employing a variety of particulate, glue, or coil methods may be used as an adjunct prior to craniotomy and surgical removal. 3, 4 It has also been performed in preparation for SRS, although its role prior to radiosurgery has declined with the realization that embolization rarely leads to significant volumetric reduction. Although the flow within the AVM may change after embolization, SRS must include the original volume. In contrast, before surgical removal, embolization may provide major benefit, either by reducing flow or eliminating deep-seated feeders that would otherwise be a significant problem during AVM resection. Recanalization of embolized AVM components over time may require repeat SRS.
Surgical removal is an important option for patients with lobar vascular malformations of suitable size, especially at centers of excellence with extensive AVM experience. Incomplete removal requires adjuvant management, perhaps including radiosurgery. Spetzler and Martin, among others, defined the relationship of AVM volume, pattern of venous drainage, and location within critical areas of the brain as important considerations that help to facilitate outcome prediction at the time of surgical resection at centers of excellence. Outcomes after AVM radiosurgery do not correlate with the same predictions of the Spetzler-Martin scale when microsurgery is used. 5 Outcomes after radiosurgery may be predicted based on volume, location, age, angioarchitecture, and dose delivered. 6 SRS is an excellent management strategy for patients with AVMs Ͻ 30 mm in average diameter (for a single procedure). Staged procedures are used for larger vascular malformations or for those that were incompletely obliterated 3 years or more after an initial procedure.
The chief benefit of radiosurgery management is risk reduction; the chief deficit of radiosurgery is the latency interval that is required to achieve complete obliteration of the AVM. 7, 8 The latency interval is generally 2 to 3 years, but in selected patients it may be longer. AVM radiosurgery has been used for children not suitable for other management strategies, as well as for older patients who have significant medical risk factors for surgical removal.
◆ History of Radiosurgery for Arteriovenous Malformations
Radiation to obliterate abnormal blood vessels in the brain is a procedure that was first considered in the late 1960s. Raymond Kjellberg, using the Harvard-affiliated proton facility in Cambridge, Massachusetts, advocated proton Bragg peak stereotactic radiation during the 1970s and early 1980s. 9, 10 More than 1000 AVM patients were treated, but the dose-planning technique was quite rudimentary. The technology of the Bragg peak proton facility was designed to provide a low exit dose based on the radiophysiological characteristics of this technology. The doses that were actually used in this series of patients were quite low and do not correspond to doses that we now know may be effective in the obliteration of AVMs. Although Kjellberg maintained that Bragg peak radiation stabilized AVM blood vessel walls and reduced the subsequent risk of hemorrhage (in comparison to age-related survivals from a life insurance table), only 20% of patients had complete obliteration of their AVM over time. Fabrikant et al, working at the Lawrence Livermore National Laboratory, began to use helium ion beam to perform multisession AVM irradiation in the 1980s.
11
In Stockholm, Lars Leksell and Ladislau Steiner initiated work with the first-generation Leksell Gamma Knife unit. 12 The first patient was treated in March 1970, using the original prototype 179 cobalt source photon beam unit designed by Borje Larsson and Lars Leksell. The target definition was based on biplane angiography done during the procedure itself. Patients were observed for a period of time in preparation for a larger experience that began to emerge in Stockholm using the second-generation unit, which was built in 1975.
Linear accelerator (linac) technologies have been adapted for SRS. O.O. Betti, working in Paris and Buenos Aires, 13 J.L. Barcia-Salorio in Spain, 14, 15 and Colombo in Vincenza, Italy, [16] [17] [18] were pioneers in the application of photon radiation using newer generation linacs. In addition, surgeons and radiation oncologists working at the Joint Center in Boston 19 and in Gainesville, Florida, 20 used modified linacs to treat a large number of vascular malformations. Most centers continue to evaluate SRS as part of an overall management plan that may include embolization, microsurgical removal, or radiosurgery alone or in combination. We will discuss our current viewpoint relative to the role of embolization subsequently.
◆ Radiosurgery for Arteriovenous
Malformations at the University of Pittsburgh
History
Our first AVM patient was treated in August 1987, 21 and we reported our initial experience in 227 patients in 1991. 22 Confirming the work of others, we noted that the 2-year Intracranial Stereotactic Radiosurgery success rate in terms of complete obliteration was related to nidus volume and dose. In high-dose cases (AVM Ͻ l cc), obliteration rates of 100% were noted, which declined to 85% for volumes of 1 to 4 cc and 58% for AVMs Ͼ 4 cc in volume.
Our subsequent 20-year experience in Pittsburgh has now increased to more than 1100 patients who have undergone Gamma Knife radiosurgery for their AVM using one or more radiosurgical procedures. We have more recently analyzed the outcome data of 906 patients who underwent radiosurgery between 1987 and 2004 (Tables 5.1, 5.2, and 5.3). Our median patient age was 36 years, with a range of 3 to 80 years. Typical symptoms at presentation included hemorrhage (46%), seizures (24%), and headache (18%). Eight percent had neurologic deficits (8%). An incidental AVM was detected in 4% of patients. Prior management strategies included surgical removal or clot evaluation in 7%. Twenty-one percent underwent one or more interventional procedures (embolization). The median target volume was 3.4 cc (range 0.065-57.7 cc). The median margin dose was 20 Gy (range 13-32 Gy). A single procedure was performed in 865 (95.5%) of patients, and repeat radiosurgery for incomplete nidus obliteration after 3 years was needed in 113 (12.5%) patients. Prospective volume staged radiosurgery was performed in 41 (4.5%) patients.
At a median follow-up of 3 years, complete nidus obliteration was achieved in 78% (confirmed by angiography or MRI). In addition, 21% of patients achieved subtotal obliteration of the nidus. During the follow-up interval, 38 bleeds (4.1%) occurred after the procedure. Seizure control was improved in 51% of patients who presented with seizures. Adverse radiation effects (AREs) resulting in neurologic deficits developed in 24 patients (2.6%) and the detection of new T2 signal increase surrounding the AVM target in 108 patients (12%). We noted long-term complications such as delayed cyst formation and encephalomalacia in 16 patients (1.7%). No patient in this AVM series has developed a radiation-related tumor at the time of this writing.
Stereotactic Radiosurgical Procedure
We perform intracranial radiosurgery using the Leksell Gamma Knife (Elekta Instruments AB, Stockholm, Sweden), beginning with the model unit U, and proceeding to the B, C, 4-C, and in recent experience Perfexion model. The patient's clinical studies and imaging are reviewed for suitability for SRS. As noted previously, we evaluate the bleeding history, the age of the patient, existing comorbidities, location, and clinical symptomatology. Patients with lobar AVMs were placed prophylactically on anticonvulsants for a period of 2 to 4 weeks around the time of the procedure. This has reduced the risk of a perioperative seizure event from as high as 5% in year 1 of our 20-year experience to a risk of Ͻ 1% at the current time. We require that all women within the child-bearing age have a recent negative pregnancy test, or we perform it on the day of the procedure. Patients are evaluated preoperatively by the neurosurgeon, the radiation oncologist, and the nursing team. On the morning of the procedure, the patients arrive at 6 o'clock and begin conscious sedation using oral lorazepam followed by intravenous (IV) conscious sedation (fentanyl and midazolam) as needed. Scalp anesthetic injection using a combination of Marcaine and Xylocaine is injected at the sites of pin application. At the current time, we prefer to use titanium pins with plastic inserts, to minimize the risk of MRI artifacts. General anesthesia may be required for frame application in imaging in patients younger than 12 years of age.
Stereotactic Radiosurgery for Arteriovenous Malformations

31
Neurodiagnostic imaging follows using both IV paramagnetic contrast-enhanced three-dimensional (3D) volumetric MRI scan and a whole-head T2 fast spin echo imaging sequence. Patients subsequently undergo biplane digital subtraction angiography (DSA) as the next step. In patients where MRI scans are not possible (those with undetermined implants, pacemakers, old aneurysm clips, etc.), we use contrast-enhanced stereotactic computed tomography angiography (CTA). The development of axial imaging as part of the imaging paradigm is critical for AVM management. This has allowed us to make superior 3D conformal plans much more carefully in comparison to using two-plane angiography alone.
Imaging studies are placed in a dose-planning computer system (Elekta Instruments), which currently has both high speed and high resolution. We begin the planning using MRI while the patient is undergoing angiography. Angiography is used to "fine-tune" or idealize the angiographic plan. In both the 4-C and Perfexion models currently used, optimization of the dose planning is achieved by confining the sharpest fall-off isodose (usually the 50%) to the edge of the 3D defined volume. Each slice is looked at serially to confirm excellent conformality (conforming the edge dose to the 3D target volume). High selectivity (rapid fall-off of the radiation dose outside the target) is equally important (Fig. 5.2) . We also assess the patient for the presence of proximal and intranidal aneurysms. We strive to reduce dose to draining veins when feasible. Typical doses at the margin of the AVM are 18 to 25 Gy and never below 16 Gy. Maximal doses are usually 36 to 50 Gy at the margin of the AVM. Final dose selection depends on the volume and location, which also helps to estimate ARE risks. We also consider the presence of preexisting neurologic conditions, the patient's age, and prior bleeding history. Because the dose to the surrounding brain is a critical predictor of ARE, we must maximize conformality and selectivity.
At the conclusion of the procedure, patients receive 20 to 40 mg of methylprednisolone. This coupled with anticonvulsants in lobar AVM patients tends to reduce the risk of perioperative seizures. For those patients who have previously undergone embolization in an attempt to reduce flow or to achieve volumetric reduction of the AVM, or for those who have had intracranial surgery or hematoma evacuation, Gamma Knife radiosurgery may be used as an adjuvant strategy rather than a primary management. We often perform radiosurgery once the patient has achieved stable neurologic improvement but almost never within the first month after an ictal event, such as a bleed or embolization. For patients who have had intracranial hemorrhages, we prefer to wait between 1 and 3 months to see if there will be a regional clot reabsorption. The AVM nidus should not be compressed by clot at the time of the radiosurgery. Failure of radiosurgery can be traced in some ways to inadequate planning, inadequate recognition of the 3D geometry of the AVM, reappearance of a component of the AVM previously embolized, or reappearance of a component of the AVM that was previously compressed by intracerebral hematoma.
Follow-up imaging is recommended at regular intervals. Whenever possible, imaging is done at our center, but if the patient lives a distance, we recommended the images be done at an imaging site closer to home. Communication with the patient's referring physician team is critical. We normally recommend MRI scans at 6 months and then annually to assess the effect of radiosurgery. If at the end of 3 years MRI suggests complete obliteration, then we request that a repeat DSA be performed. If MRI clearly defines residual nidus, angiography is delayed, and the patient is contacted to suggest the possible need for repeat radiosurgery to achieve the final obliteration response. In such cases, repeat stereotactic imaging may include both repeat MRI and angiography.
For those patients who have large AVMs (determined by multiplying the MRI X, Y, and Z dimensions of the AVM and dividing by 2, a rough approximation of an ellipsoid volume), we recommend consideration of prospective staged SRS. Staged radiosurgery, with two stages separated usually by 3 months, is recommended for AVMs Ͼ 15 cm 3 . We also consider it for those AVMs between 10 and 15 cm 3 . For those AVM volumes 10 cm 3 or smaller, we normally perform single-stage radiosurgery. The interval between stages varies from 3 to 6 months based on the goal of some radiobiological repair of surrounding brain during the observation interval. However, we do not want to wait too long, as the goal of protection from bleeding cannot begin until the radiosurgical procedure has been completed for all volumetric components of the AVM.
◆ Current Outcomes of Stereotactic Radiosurgery of Arteriovenous Malformations
In the absence of treatment, the overall risk of a spontaneous bleed from a brain AVM appears to range from 1 to 5% per year, depending on various risk factors. 23 In the Finnish population-based 24-year study, hemorrhage was a relatively constant lifetime risk, with an annual death risk of ϳ1% and approximately a 4% risk of bleed per year. 23 Recent work reported from the cooperative trial in Canada suggested that an annual bleed rate may be as high as 5% (C Wallace, personal communication). We performed an individualized analysis of the hemorrhage risk of AVM patients before radiosurgery. 24 Our findings demonstrated an overall crude annual hemorrhage rate of 2.4% per year.
There were several factors associated with hemorrhage risk, the primary one being a prior hemorrhage (an identification of a single draining vein on angiography), along with the detection of a diffuse AVM nidus on angiography. Pollock et al constructed an estimation of bleed risks related to these significant factors 24 ( Tables 5.4 and 5.5). For low-risk AVMs (no prior hemorrhage and no other risk factors, diffuse nidus, or single draining vein), the annual risk rate was ϳ1% per year. In contrast, the risk of a second hemorrhage for patients with additional risk factors ranged from 2.0 to 3.7% for AVMs with a compact nidus up to 8.94% for those with high-risk features of the angioarchitecture (one draining vein or diffuse morphology).
In talking with families, we often use a "rule of thumb" to estimate the lifetime bleeding risk related to a patient's age. The age at which the risk of a bleed is greater than the risk of morbidity from radiosurgery may well depend on the location and size of the AVM. A simple lifetime analysis risk rate suggests that a patient's age subtracted from 105 will give the total cumulative risk of that patient having a bleeding event. 25, 26 Clearly, for a child, the risk is very large, whereas for a senior citizen, the remaining lifetime risk of a bleed for a patient who has never bled before may be reasonably low.
Bleeding Risks after Stereotactic Radiosurgery for Arteriovenous Malformations
We have also analyzed the bleeding rate during the observation interval (latency interval) after radiosurgery and before 27 For this study, we evaluated 312 patients with clinical angiographic outcomes followed for an average of 4 years. Twenty-one patients suffered AVM bleeds at a median of 8 months after radiosurgery. The overall total risk of postradiosurgery hemorrhage per patient was 7.4%, after exclusion of additional bleeding risk factors such as untreated aneurysms. The actual hemorrhage rate from a patent AVM before complete obliteration was 4.8% per year during the first 2 years after radiosurgery, and 5% per year for the third to fifth years after radiosurgery, if the AVM continued to be unobliterated. Our data have not provided strong evidence to date that there is a protective benefit of radiosurgery that gradually emerges during the observation years, even before complete obliteration has occurred. In contrast, studies from the University of Tokyo experience reported by Maruyama et al 28 as well as reinterpretation of the outcome data from the Karolinska experience 29 of Steiner have suggested that there may be some protective benefit to AVMs even before complete obliteration of their nidus occurs.
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Patients who have a proximal unsecured aneurysm have an increased risk of postradiosurgical hemorrhage. If the aneurysm is immediately proximal to the AVM, it will likely close as the AVM obliterates. We have not found that intranidal aneurysms increase the risk of bleeding during the latency interval. For those patients with aneurysms more than one arterial branch proximal to their AVM, we believe that the aneurysm requires a different management algorithm that should be determined based on those characteristics that guide whether surgery or endovascular is the best management. Such aneurysms generally do not go away at the time that the AVM is obliterated.
To date, in our experience, no patient has suffered a hemorrhage after definitive high-resolution angiography has confirmed complete obliteration of their AVM. We have a single patient with more than 50 aneurysm clips who has undergone multiple surgical procedures. The AVM was thought to be obliterated after radiosurgery, but the patient suffered a subsequent hemorrhage. A new AVM was identified on follow-up angiography (neither CT nor MRI scan was feasible in this patient). The possibility of recanalization of a previously treated AVM requiring additional treatment and monitoring is important. For this reason, even in those patients who have angiographic complete closure of their AVM, we recommend MRI scans at 2-year intervals to assess the overall brain response to detect late ARE or delayed cyst development.
Although the studies of both Maruyama et al and Karlsson et al 28, 29 provide some evidence of an overall reduction in bleeding rates during the latency interval, this hypothesis remains largely unproven at the present time. In addition, both ours and other outcome studies have shown that even with complete obliteration, the hemorrhage rate is not zero. For patients who have defined angiographic obliteration, we may safely estimate that the lifetime risk of a bleed is now Ͻ 1%.
Arteriovenous Malformation Obliteration after Stereotactic Radiosurgery
In our study of 351 patients followed for 3 to 11 years by imaging, and using dosages at the margin of 20 Gy (median), we documented AVM obliteration (Fig. 5.3) in 73% of those patients studied by angiography and in 86% of those patients studied by MRI alone. 30 Furthermore, we believe that there is approximately a 95% accuracy that MRI-detected obliteration will be confirmed by follow-up angiography. 31 There are some patients who are unwilling to undergo repeat angiography even though this remains the gold standard for detection of response. Even the presence of an early draining vein, without discernible nidus, is a sign of satisfactory response. To our knowledge, no patient has subsequently bled when only an early draining vein is seen. Follow-up angiography afterwards at 6 months to 1 year in such cases invariably shows loss of the early draining vein as well.
Failure of obliteration is multifactorial and as noted earlier may be related to dose, volume, inadequate recognition of the 3D geometry, recanalization of the previously embolized component, or clot-compressed AVM that was 
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subtotally treated. In our studies designed to detect the reasons for marginal failure, we noted that such persistence of out-of-field residual AVM was seen in 18% of previously embolized patients but only 5% of nonembolized patients. We have also noted that the successful obliteration for the same-volume AVMs may be slightly lower in women, is higher in children, and occurs more completely and at a faster rate in children than in adults.
Adverse Effects of Radiosurgery
Early adverse effects are relatively rare and include headache from the frame application, nausea from conscious sedation medications, and the relatively small risk of developing seizures in patients with subcortical lobar AVMs. [31] [32] [33] [34] It is for this reason that prophylactic anticonvulsants are used in these patients but not in patients with deep-seated AVMs. Late AREs of radiosurgery are relatively rare. We evaluated data from 85 AVM patients who developed symptomatic complications after Gamma Knife radiosurgery and compared them with 337 patients who had no complications and were evaluated as part of another multiinstitutional study. 35 Thirty-five of 85 patients were classified as having a permanent symptomatic sequela. We constructed various models to study the effects of AVM location and the volume of tissue receiving 12 Gy or more (the 12 Gy volume) with the risk of developing permanent postradiosurgery ARE. AVM locations in increasing order of risk as might be expected were frontal, temporal, interventricular, parietal, cerebellar, corpus callosum, occipital, medulla, thalamus, basal ganglia, and pons and midbrain. We were able to construct statistical models predicting the risk of permanent radiation sequelae with a 12 Gy volume. Such data are very important for subsequent planning of additional patients relative to a risk/benefit analysis. This database, though useful, was constructed with a relatively small number of complications, considering the large number of patients and the relatively large number of variables. It is likely that the risk predictions for some brainstem locations are significantly overestimated. Certainly, the risk of complications is expected to be high for large-volume AVMs in critical locations of the brain (Table 5.6). It is for this reason that for larger volume AVMs, 15 cc or more, we clearly recommend staging. The goal of this is to increase the eventual obliteration rate while maintaining safety. We generally divide the AVM into two volumes of approximately equal proportion. At the time of the first procedure (which is done with angiography and MRI), we devise a plan for the Abbreviation: AVM, arteriovenous malformation. *Marginal doses were chosen according to 3% guidelines from the integrated logistic formula. 32 Because of limited experience, estimated brainstem risks are probably less than predicted in this table.
entire AVM and then gradually subtract isocenters from the plan until we develop a 50% volume that corresponds to the initial stage. The second-stage volume is then done to reproduce the original plan at an interval of 3 to 6 months. This strategy increases the brain's ability to repair normal tissue and to prevent AREs.
Other complications of AVM radiosurgery are relatively rare. Such complications have taken many years to fully understand or even develop. These include the risk of hemorrhage despite obliteration (1% lifetime), the risk of temporary or permanent radiation injury, the risk of late cyst formation at the site of the obliterated nidus, and the long-term risk for radiation-induced tumor. Cyst formation after AVM radiosurgery was first reported by Japanese investigators who had sent patients to receive Gamma Knife radiosurgery in Sweden in the early years of radiosurgery. 36 Cyst formation has also been reported in other long-term follow-up studies. 37, 38 In our 20 years of experience, we have detected 16 patients (1.7%) with delayed cyst formation. We also observed that patients who developed delayed cyst formation were more likely to have had prior bleeds. This raises the intriguing possibility that residual iron deposition in the brain tissue may serve as a radiation sensitizer that could potentiate the effects of radiosurgery on a long-term basis. Such cysts have been managed with observation, simple drainage, cyst shunting, or surgical fenestration. Patients with perioperative T2 signal change without additional neurologic problems do not require additional treatment.
In our experience of almost 9000 Gamma Knife procedures, we have not identified a patient who fits the Cahan requirements for a radiation-related tumor. Recently, Sheehan et al reported two patients who have had radiosurgery for their AVM and developed delayed meningiomas. 39 As a relatively common tumor in older patients, it is not clear from a population basis that this represents a significant increased risk compared with the natural history of meningioma development. There are, however, two additional cases of a glioblastoma reported after AVM radiosurgery. 40, 41 With more than a half million patients having undergone Gamma Knife radiosurgery over the last 40 years, the denominator (number treated) is relatively known, but the numerator (the incidence of radiation-related tumors) remains largely an estimate. We provide an estimate to patients that the gross risk of developing a radiation-related tumor is ϳ4 in 50,000, a 1 in 12,500 risk. We do, nonetheless, warn our patients the risk of a radiation-related tumor may be as high as 1 in 1000, although neither our personal experience nor data recently published from Sheffield, England, can confirm this incidence. 42 
Repeat Radiosurgery
For those patients who have a residual nidus identified by imaging 3 or more years after radiosurgery, we recommend repeat radiosurgery. For such patients, we are occasionally able to increase the dose slightly to the residual smaller volume AVM. Permanent neurologic injury was slightly higher than would be expected with those patients who had no prior radiation injury. 43 However, it should be recalled that most patients had relatively larger AVMs to begin with and received relatively lower radiation margin doses. If we are unable to give in a single procedure 16 Gy or more, we believe that staged radiosurgery must be considered to try to increase the chances of the obliteration rate. We know that the successful obliteration response declines rapidly below a 15 Gy edge dose.
◆ The Management of Large Arteriovenous Malformations
Large AVMs pose a major challenge for both surgical resection embolization and radiosurgery. Multimodality management is probably going to be critical for such AVMs that have any hope of treatment. AVM embolization has been performed using a variety of agents over the course of time, including isobutyl cyanoacrylate glue, coils, silk threads, polyvinyl alcohol, and, more recently, Onyx (ev3 Neurovascular, Irvine, CA). Prior studies have shown the recanalization rates of 14 to 15% of patients who had prior AVM embolization. Because we cannot use a single-staged radiosurgical procedure for such large-volume AVMs, we have recommended a staged prospective approach. Although fractionated radiation therapy (2-4 Gy per fraction to a total dose of 50 Gy) has virtually no significant benefit 44 in terms of AVM obliteration and at the same time has significant long-term side effect risks, radiosurgery divided into two sessions seems to have an acceptable risk prediction. Kjellberg et al, using stereotactic Bragg peak radiation therapy, achieved obliteration rates Ͻ 20%, although they postulated that such radiation-stabilized blood vessel walls reduced the risk of a subsequent bleed. 10 Most of the AVMs treated by this technique had large-volume AVMs. In a group of 48 patients treated by Pan et al, 45 an obliteration rate of only 25% was noted after 14 months in a single radiosurgical strategy when relatively larger doses were given to the edge . Approximately 37% of patients had moderate and 12% severe adverse radiation effects when the AVM volume was Ͼ 10 cc. We noted the rather narrow window between dose response and complication, as well as the minimal chance of receiving a total obliteration with low dose. We switched to prospective volume staging (Fig. 5.4) as an option to manage larger AVMs unsuitable for primary single-session radiosurgery.
◆ The Role of Preradiosurgical Embolization
Embolization has a major benefit in preparation for craniotomy and microsurgical removal. 46 Its primary benefit is reducing the flow through the AVM or removal of deep-seated feeders that may be problematic for subsequent surgical removal. We used embolization early in our experience for larger volume AVMs. 47 The goal was to decrease the volume of the AVM to make it more effective for radiosurgery.
However, embolization can be effective only if it permanently reduces the nidus volume. Reduction in flow from an AVM does not provide improvement in radiosurgical outcome data. Our most recent analysis suggests that radiosurgical embolization had a negative effect on AVM obliteration rates. 48 Others have reported that up to 30% of patients who had AVM embolization subsequently had an increase in the nidus volume when a subsequent angiogram was performed at the time of radiosurgical targeting. 49 Twelve percent of embolized AVMs showed recanalization within a year. 50 Unlike surgery that removes an AVM nidus within a few weeks of embolization, radiosurgery takes several years to be fully effective. This latency interval, unfortunately, allows sufficient time for embolized AVM components to recanalize, remodel, or even recruit new feeding blood vessels. In a recent report using both embolization and radiosurgery, permanent neurologic deficits ranged from 5 to 12% of patients, with a mortality rate of 1.5 to 2.7% of patients. [49] [50] [51] Complete obliteration rates varied from 47 to 55%. [49] [50] [51] In a study of 47 patients who had radiosurgery and embolization in comparison to 47 matched patients who were treated with radiosurgery alone, nidus obliteration was achieved in 47% of the embolization group but in 70% of the radiosurgery group. 52 The experience using adhesive agents such as Onyx is too early yet to define whether radiosurgery will have a significant improvement in patients who have previously undergo liquid adhesive embolization.
◆ Treatment of Dural Arteriovenous Malformations
In contrast to the experience with intracranial AVMs, dural vascular malformations or dural arteriovenous fistulas (DAVFs, Fig. 5 .5) may indeed benefit from embolization and radiosurgery. 53 The timing of the individual procedures is critical. In general, we prefer to do radiosurgery first in a newly diagnosed patient, at a time when the entire connection of the fistula can be defined. Most of these lesions occur in the region of the transverse or sigmoid sinus and may be associated with pulsatile tinnitus. 54 Others may occur in the cavernous sinus and are associated with diplopia, impaired vision, or exophthalmos. Lesions of the superior sagittal sinus may cause papilledema, vision loss, and hydrocephalus. Those lesions that have cortical venous drainage are prone to have intracranial hemorrhages, progressive deficits, or seizures. Because such patients have an overall intracranial hemorrhage rate of ϳ2% per year, management of these lesions may be very important. 54 We generally recommend early radiosurgery followed the same day by embolization. Patients have their frame placed and undergo MRI, followed by initial angiography, and are transferred to Gamma Knife for radiosurgery with a femoral sheath catheter left in position. After completion of the radiosurgical component of the procedure, they are transferred back to the interventional radiology suite, where they undergo embolization. The combination of radiosurgery and embolization provides both early symptom relief of the DAVF and long-term relief of the condition by radiosurgery.
◆ Summary
AVM radiosurgery is a well-established management strategy for AVMs at the present time. With more than 25 years of experience using Gamma Knife technique, and with thousands of patients worldwide who have undergone this procedure, we understand the overall success rate, the complication rate, and the various alternative strategies. We believe that at the present time embolization has an important role prior to microsurgery, an important role after radiosurgery for the management of DAVFs, and a relatively limited role in the prospective management of AVMs within the brain. Although outcome studies continue to be looked at both in Canada and in the United States, we suspect that most patients with an intracranial AVM require strong consideration for intervention, providing the management strategy has an acceptable risk to the patient. It seems unlikely that higher doses will be feasible. The ability to conform dose and to restrict dose (selectivity) seemed to be maximized with the current imaging techniques as well as radiation delivery systems, including the new Perfexion Gamma Knife. We may be able to increase the chance of obliteration by developing specific radiation sensitizers delivered by microcatheters immediately before radiosurgery. To date, brain protection technologies and drugs have been disappointing. The greatest remaining issue for AVM radiosurgery is the risk of a latency interval hemorrhage, so efforts to reduce the latency interval would be important. The recognition of late long-term side effects, including the possible risk of radiation-related tumors or late cyst development, continues to be evaluated. Within the context of a disease that has a 1% annual mortality left untreated, the current data have shown that SRS is a safe and effective management strategy that can be applied to both lobar and deep-seated AVMs. Many patients with AVMs were never treatable by any technique prior to the development of radiosurgery. 
